Ciclosporin - Cellgate

Drug Profile

Ciclosporin - Cellgate

Alternative Names: CGC 1072; CGC 1072 analogue - Cellgate; CGC 2001; Cyclosporin modified - Cellgate; Cyclosporine modified - Cellgate; PsorBan

Latest Information Update: 09 Aug 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellgate
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 09 Aug 2007 Discontinued - Phase-II for Psoriasis in USA (Topical)
  • 05 May 2003 Clinical data from a media release have been added to the pharmacokinetics and the Skin Disorders and Drug Delivery Systems therapeutic trials sections
  • 09 Apr 2003 Data presented at the 61st Annual Meeting of the American Academy of Dermatology (AAD-2003) have been added to the adverse events and Skin Disorders and Drug Delivery Systems therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top